A neuroblastoma-specific panel using NGS could be developed to identify more comprehensive genomic information to molecularly treat and predict prognosis with sophistication based on genomic characteristics such as MYCN, TERT, ATRX, ALK, ARID1, and telomere length. This evidence concerns the gene TERT and neuroblastoma.